KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV), a clinical stage pharmaceutical company, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET.

A live webcast will be available on the company's website, followed by an audio archive accessible for 30 days. KalVista focuses on small molecule protease inhibitors targeting unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a virtual fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.

A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.

Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 2 KOMPLETE clinical trial, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005024/en/

KalVista Pharmaceuticals, Inc.

Ben Palleiko

CBO & CFO

857-999-0890

investors@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

When will KalVista Pharmaceuticals participate in the SVB Leerink Global Healthcare Conference?

KalVista Pharmaceuticals will participate in the SVB Leerink Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET.

Where can I find the webcast of KalVista Pharmaceuticals' presentation?

The webcast of KalVista Pharmaceuticals' presentation will be available on their website at www.kalvista.com.

What is the main focus of KalVista Pharmaceuticals?

KalVista Pharmaceuticals focuses on discovering, developing, and commercializing small molecule protease inhibitors for diseases with significant unmet medical needs.

What are the key products being developed by KalVista Pharmaceuticals?

KalVista is developing KVD900 for acute hereditary angioedema attacks and KVD824 for prophylactic treatment of hereditary angioedema, among other therapies.

How long will the audio archive of the conference presentation be available?

The audio archive of KalVista Pharmaceuticals' conference presentation will be available for 30 days after the event.